Shouxiangu(SH:603896)2025-10-28 07:55Financial Performance - The company's operating revenue for Q3 2025 was ¥130,454,533.70, representing an increase of 8.51% compared to ¥119,452,348.03 in the same period last year[4] - The total profit for Q3 2025 decreased by 30.32% to ¥10,718,962.04 from ¥17,734,027.88 in the previous year[4] - The net profit attributable to shareholders for Q3 2025 was ¥10,783,105.44, down 30.15% from ¥17,797,076.96 year-on-year[4] - The basic earnings per share for Q3 2025 was ¥0.06, a decrease of 25.00% from ¥0.09 in the previous year[4] - Total operating revenue for the first three quarters of 2025 was CNY 430,138,219.40, a decrease of 10.23% compared to CNY 479,159,858.20 in the same period of 2024[18] - Operating profit for the first three quarters of 2025 was CNY 76,143,011.62, down 33.8% from CNY 114,914,017.94 in the first three quarters of 2024[19] - Net profit for the first three quarters of 2025 was CNY 76,346,218.54, a decline of 33.5% compared to CNY 114,746,646.06 in the same period of 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 0.39, down from CNY 0.58 in the first three quarters of 2024[20] - The company reported a total comprehensive income of CNY 77,292,555.07 for the first three quarters of 2025, down from CNY 133,979,766.79 in the same period of 2024[19] Cash Flow - The net cash flow from operating activities increased by 51.24% to ¥20,940,482.65 compared to ¥14,339,593.21 in the same quarter last year[4] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 516,959,357.49, a decrease of 6.2% compared to CNY 551,162,261.17 in the same period of 2024[21] - The net cash flow from operating activities remained stable at CNY 143,934,561.17, slightly up from CNY 143,020,961.88 year-on-year[21] - Cash inflow from investment activities was CNY 508,582,834.33, down 61.4% from CNY 1,317,521,596.31 in the previous year[22] - The net cash flow from investment activities was negative at CNY -248,258,120.35, compared to a positive CNY 219,995,039.05 in the same period last year[22] - Cash inflow from financing activities totaled CNY 338,161,710.00, a decrease of 14.2% from CNY 393,983,609.10 in 2024[22] - The net cash flow from financing activities was negative at CNY -69,273,180.35, improving from CNY -244,724,725.20 in the previous year[22] - The total cash and cash equivalents at the end of the period decreased to CNY 133,160,363.81 from CNY 694,537,534.64 a year earlier, reflecting a significant decline of 80.9%[22] - The company received CNY 505,000,000.00 from investment recoveries, down from CNY 1,090,700,000.00 in the previous year, indicating a 53.7% decrease[21] - The cash paid for purchasing fixed assets and other long-term assets was CNY 207,297,228.65, a reduction of 55.3% compared to CNY 463,526,557.26 in the same period of 2024[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,154,624,430.70, reflecting a slight increase of 0.73% from ¥3,131,185,579.81 at the end of the previous year[5] - The company's total assets as of September 30, 2025, amount to ¥3,154,624,430.70, compared to ¥3,131,807,017.80 as of December 31, 2024[14] - Current assets total ¥1,436,703,862.13, a decrease from ¥1,520,659,727.33 in the previous year[14] - Total liabilities as of the reporting date were CNY 841,887,672.83, slightly up from CNY 840,519,671.65 in the previous period[16] - Total equity increased to CNY 2,312,736,757.87 from CNY 2,291,287,346.15, reflecting a growth of 0.93%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,715[11] - The largest shareholder, Zhejiang Shouxian Valley Investment Management Co., Ltd., holds 56,711,239 shares, accounting for 28.61% of total shares[12] Research and Development - The company reported a significant increase in research and development expenses by 32.32% due to increased investment in R&D[9] - Research and development expenses for the first three quarters of 2025 were CNY 42,091,658.84, an increase of 32.2% compared to CNY 31,810,538.64 in the same period of 2024[18] Other Financial Metrics - The weighted average return on equity decreased by 0.26 percentage points to 0.48% in Q3 2025 from 0.83% in the same period last year[4] - The company experienced a 54.48% decrease in net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period[9] - The company completed the acquisition of 100% equity in Hangzhou Shouxian Valley Health Pharmacy Chain Co., Ltd., which constitutes a business combination under common control[5] - Sales expenses decreased to CNY 184,212,580.12 from CNY 215,945,990.95, a reduction of 14.7%[18] - Other income for the first three quarters of 2025 was CNY 35,722,954.55, an increase from CNY 20,381,829.94 in the same period of 2024[18] - The company did not apply new accounting standards for the current year, maintaining consistency in financial reporting[23]